Evaluation of the effect of favipiravir on patients with COVID-19

BACKGROUND: The novel coronavirus disease 2019 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) started in December 2019 in Wuhan, China. No specific drug has been accepted for COVID-19 treatment up to now. Favipiravir as an antiviral drug affects RNA viruses like influenza and...

Descripción completa

Detalles Bibliográficos
Autores principales: Kamali, Alireza, Sarmadian, Hossein, Mahmoodiyeh, Behnam, Valibeik, Shamim, Farmani, Farzane, Bashirgonbadi, Zahra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10114572/
https://www.ncbi.nlm.nih.gov/pubmed/37091030
http://dx.doi.org/10.4103/jfmpc.jfmpc_1058_22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10114572/
https://www.ncbi.nlm.nih.gov/pubmed/37091030
http://dx.doi.org/10.4103/jfmpc.jfmpc_1058_22

Ejemplares similares